文献速递前列腺癌

局部治疗和/或转移灶导向治疗在激素敏感性M1a前列腺癌患者中的作用——一项系统综述

Role of Local and/or Metastasis-directed Therapy in Patients with Hormone-sensitive M1a Prostate Cancer-A Systematic Review.
PubMed 文献 · Eur Urol Oncol · 2022-11-10

该系统综述检索Medline、Embase和Scopus,共筛选6136篇文章,纳入24项研究,评估前列腺导向治疗(PDT)和/或转移灶导向治疗(MDT)对激素敏感性M1a前列腺癌的肿瘤学结局。在新发M1a患者中,PDT与改善肿瘤学结局相关;在复发M1a患者中,MDT可能延迟部分患者开始全身治疗的需要,但尚待前瞻性III期随机对照试验的高级别证据。

要点

  • 在新发M1a前列腺癌患者中,PDT与改善肿瘤学结局相关。
  • 在复发M1a前列腺癌患者中,MDT可能延迟部分患者开始全身治疗的需要。
  • 纳入研究以回顾性为主且设计异质性显著,限制证据强度。

核心结论

  • 亚组分析提示PDT联合全身治疗在新发M1a前列腺癌中可能起作用。
  • 在复发M1a前列腺癌中,针对远处淋巴结转移的MDT延迟了开始全身治疗的需要,但缺乏稳健数据。

研究设计与样本

  • 系统综述,按照PRISMA指南检索Medline(Ovid)、Embase和Scopus。
  • 共筛选6136篇文章,纳入24项研究。
  • 纳入接受PDT(根治性前列腺切除术或放疗)和/或MDT(淋巴结放疗或挽救性淋巴结清扫)联合或不联合雄激素剥夺治疗的新发或复发激素敏感性M1a前列腺癌患者的肿瘤学结局报告。
  • 进行了描述性数据合成和方法学质量评估。

主要发现

  • 在新发M1a前列腺癌患者中,PDT与相比未接受PDT改善的肿瘤学结局相关。
  • 在复发M1a前列腺癌中,MDT可能延迟部分患者开始全身治疗的需要。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 纳入研究以回顾性为主。
  • 研究设计存在显著异质性,限制证据强度。
  • 尚待前瞻性III期随机对照试验的高级别证据。
  • 缺乏稳健数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: It remains unclear whether men with hormone-sensitive prostate cancer (PCa) metastasized to nonregional lymph nodes (M1a) benefit from prostate-directed therapy (PDT) and/or metastasis-directed therapy (MDT). OBJECTIVE: To systematically summarize the literature regarding oncological outcomes of de novo and recurrent M1a PCa patients treated with PDT and/or MDT. EVIDENCE ACQUISITION: We searched Medline (Ovid), Embase, and Scopus according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines for reports on oncological outcomes of de novo or recurrent hormone-sensitive M1a PCa patients treated with PDT (radical prostatectomy or radiotherapy) and/or MDT (nodal radiotherapy or salvage lymph node dissection) with or without androgen deprivation therapy. A descriptive data synthesis and a methodological quality assessment were performed to evaluate the impact of PDT and/or MDT on survival in M1a PCa patients. EVIDENCE SYNTHESIS: A total of 6136 articles were screened and 24 studies were included in this systematic review. In de novo M1a PCa patients, PDT was associated with improved oncological outcomes compared with no PDT. In recurrent M1a PCa, MDT could delay the need for systemic treatment in a selection of patients, but high-level evidence from prospective phase III randomized controlled trials is still awaited. CONCLUSIONS: This systematic review summarized the limited literature data on the management of M1a PCa. Subgroup analyses suggest a role for PDT plus systemic therapy in de novo M1a PCa. MDT to distant nodal metastases delayed the need for systemic therapy in recurrent disease, but robust data are lacking. The predominantly retrospective nature of the included studies and significant heterogeneity in study designs limit the strength of evidence. PATIENT SUMMARY: We reviewed the treatment of patients with prostate cancer that has spread to lymph nodes outside the pelvis without metastases in other organ systems. There is evidence that treatment of the primary prostate tumor improves outcomes in well-selected patients and that treatment targeting distant lymph node metastases can delay the start of systemic treatment.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. de Barros HA, van Beurden I, Droghetti M, et al. Role of Local and/or Metastasis-directed Therapy in Patients with Hormone-sensitive M1a Prostate Cancer-A Systematic Review. Eur Urol Oncol. 2022. PMID: 36372736. doi:10.1016/j.euo.2022.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。